Urinary F2-Isoprostanes as a Biomarker of Reduced Risk of Type 2 Diabetes

Abstract

OBJECTIVE We have previously reported evidence of an inverse association between a urinary F2-isoprostane and type 2 diabetes risk in a pilot case-control study nested within the Insulin Resistance Atherosclerosis Study (IRAS). Here, we report the results from the study extended to the entire IRAS cohort. RESEARCH DESIGN AND METHODS This prospective study included 138 incident type 2 diabetes case and 714 noncase subjects. Four F2-isoprostanes (iPF2α-III; 2,3-dinor-iPF2α-III; iPF2α-VI; and 8,12-iso-iPF2α-VI) were assayed in baseline urine samples using liquid chromatography–tandem mass spectrometry. RESULTS Three F2-isoprostanes showed significant inverse associations with type 2 diabetes risk: the adjusted odds ratios were 0.52 (95% CI 0.39–0.67), 0.56 (0.42–0.73), 0.62 (0.48–0.79), and 0.91 (0.72–1.12) for iPF2α-III; 2,3-dinor-iPF2α-III; iPF2α-VI; and 8,12-iso-iPF2α-VI, respectively. CONCLUSIONS Our findings indicate that urinary F2-isoprostanes are inversely associated with type 2 diabetes risk beyond the traditional risk factors and may be useful in identifying high-risk populations.